Clopidogrel therapy effects on cell hemostasis in acute coronary syndrome

The study was aimed at investigating cell hemostasis parameters in acute coronary syndrome (ACS), and comparing the effects of various antiaggregant medications (clopidogrel, aspirin, or their combination) on platelet (PL) and red blood cell (RBC) aggregation activity. In total, 98 ACS patients were...

Full description

Saved in:
Bibliographic Details
Main Authors: R. A. Rakhimova, B. A. Alyavi, M. L. Kenzhaev, L. Sh. Davlatova
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2008-12-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/1642
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The study was aimed at investigating cell hemostasis parameters in acute coronary syndrome (ACS), and comparing the effects of various antiaggregant medications (clopidogrel, aspirin, or their combination) on platelet (PL) and red blood cell (RBC) aggregation activity. In total, 98 ACS patients were divided into groups, according to the antiaggregant therapy received. At Days 3-4 and 6-7, PL aggregation activity and RBC morphology and function were assessed. Antiaggregant therapy was highly effective among those receiving combined treatment, with minimal PL aggregation and maximal RBC morphology improvement (high prevalence of discocytes and reversibly deformed RBC) observed as early as Day 3 and further increasing by Day 7. All three variants of antiaggregant therapy were significantly effective, but Clopidogrel, especially in combination with aspirin, demonstrated the best effect. Combined therapy (clopidogrel and aspirin) improved cell hemostasis parameters, which could be linked to better aggregation inhibition due to different therapeutic targets for these two agents.
ISSN:1560-4071
2618-7620